Evaluation of the activity of arginase and some biochemical parameters in sera of patients with acromegaly
DOI:
https://doi.org/10.21123/bsj.2024.8784Keywords:
Arginase, Acromegaly, Growth hormone, Insulin-Like Growth Factor-1, Lipid Profile.Abstract
The objective of the present study was to study the effect of increasing Growth Hormone (GH) on arginase activity in sera of Iraqi acromegaly (ACRO) patients. Certain Vital biochemical parameters were measured such as Growth Hormone (GH), Insulin-Like Growth Factor-1 (IGF-1), Fasting Serum glucose (FSG), Urea, Total Cholesterol (TC), Triglycerides (TG), High-density lipoprotein-cholesterol (HDL-C), Low-density lipoprotein-cholesterol (LDL-C), and very low-density lipoprotein-cholesterol (VLDL-C). Eighty people between the ages ranged between of 25 and 65 were involved in this study, 40 of them were ACRO Iraqi patients and the remaining 40 were healthy controls. All participants were matched in age and sex and the body mass index (BMI) were calculated for each group. Arginase activity was reduced in ACRO patients significantly (p<0.05) compared to controls, also the HDL-C levels were reduced significantly p<0.05, while the levels of GH, IGF-1, TC, TG, LDL-C, and VLDL-C were elevated significantly p<0.05. There were no significant differences in the levels of FSG and urea between the patients and controls p>0.05. Results of the present study have revealed that patients with ACRO have significantly lower levels of serum arginase activity and not significantly lower levels of serum urea, which means their bodies retain more nitrogen compounds for use in building processes.
Received 21/03/2023
Revised 02/10/2023
Accepted 04/10/2023
Published Online First 20/05/2024
References
Bandeira F, Lemos ALP, de Lima Andrade SR. Acromegaly. In: Bandeira F, Gharib H, Griz L, Faria M, editors. Endocrinology and Diabetes: A Problem Oriented Approach. Cham: Springer International Publishing; 2022:p. 55-60. https://doi.org/10.1007/978-3-030-90684-9_6
Langlois F, Suarez GM, Fleseriu M. Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly. F1000Res. 2020; 9. https://doi.org/10.12688/f1000research.22683.1
Badiu C, Witek P. Insights Into Acromegaly Complications. Front Endocrinol. 2022; 13: 905145. https://doi.org/10.3389/fendo.2022.905145
Coronel-Restrepo N, Syro LV, Rotondo F, Kovacs K. Anatomy of the Pituitary Gland. Pituitary Adenomas: The European Neuroendocrine Association’s Young Researcher Committee Overview: Springer; 2022: 1-19. https://doi.org/10.1007/978-3-030-90475-3_1
Gierach M, Junik R. Aberrations in carbohydrate metabolism in patients with diagnosed acromegaly bservational study. Endokrynol Pol. 2022; 73(4): 743-744. https://doi.org/10.5603/ep.a2022.0034
Sibeoni J, Manolios E, Verneuil L, Chanson P, Revah-Levy A. Patients’ perspectives on acromegaly diagnostic delay: a qualitative study. Eur J Endocrinol. 2019; 180(6): 339-52.https://doi.org/10.1530/EJE-18-0925
Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications Signal Transduct. Target Ther. 2019; 4(1): 3. https://doi.org/10.1038/s41392-019-0036-y
Chesnokova V. The Multiple Faces of the GH/IGF Axis. Cells. 2022; 11(2): 217. https://doi.org/10.3390/cells11020217
Moriyama S. Handbook of Hormones: Comparative Endocrinology for Basic and Clinical. Second Edition. England: Oxford: Elsevier, Academic Press; 2021. Subchapter 24A, Growth hormone; p. 199–201. https://doi.org/10.1016/B978-0-12-820649-2.00053-X
Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019; 4(1): 3. https://doi.org/10.1038/s41392-019-0036-y
Wondisford FE. Essentials of Endocrinology and Metabolism: A Practical Guide for Medical Students: Springer Nature; 2020: p. 229–40. https://doi.org/10.1007/978-3-030-39572-8_26
Kim S-H, Park M-J. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017; 22(3): 145 .https://doi.org/10.6065/apem.2017.22.3.145
Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020; 9(9): 1970. https://doi.org/10.3390/cells9091970
AsghariHanjani N, Vafa M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. Med J Islam Repub Iran. 2019; 33(1): 1–4.
Kumari N, Bansal S. Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment. Cancer Chemother Pharmacol. 2021; 88: 565-94. https://doi.org/10.1007/s00280-021-04335-w
16. Ren Y, Li Z, Li W, Fan X, Han F, Huang Y, et al. Arginase: Biological and Therapeutic Implications in Diabetes Mellitus and Its Complications. Oxid Med Cell Longev. 2022; 20(22): 20. https://doi.org/10.1155/2022/2419412
Li Z, Wang L, Ren Y, Huang Y, Liu W, Lv Z, et al. Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases. Cell Death Discov. 2022; 8(1): 413. https://doi.org/10.1038/s41420-022-01200-4
Clemente GS, van Waarde A, Antunes IF, Dömling A, Elsinga PH. Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. Int J Mol Sci. 2020; 21(15): 5291. https://doi.org/10.3390/ijms21155291
Khaleel F, Oda NN, Abed BA. Disturbance of Arginase Activity and Nitric Oxide Levels in Iraqi Type 2 Diabetes Mellitus. Baghdad Sci J. 2018; 15(2): 189. https://doi.org/10.21123/bsj.2018.15.2.0189
Detroja TS, Samson AO. Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2. Molecules. 2022; 27(16): 5134. https://doi.org/10.3390/molecules27165134
Porembska Z, Kedra M. Early diagnosis of myocardial infarction by arginase activity determination. Clin Chim Acta. 1975; 60(3): 355–61. https://doi.org/10.1016/0009-8981(75)90078-9
Abdullah AH, Mohaisn IK, Nsaif AS, Safaryan AHM. Studying the impact of vitamin D deficiency in Iraqi acromegalic patients and its relation with some biochemical parameters. Ann Trop Med Public Heal. 2020; 23(11). https://doi.org/10.36295/ASRO.2020.231131
Sharma R, Kopchick JJ, Puri V, Sharma VM. Effect of growth hormone on insulin signaling. Mol Cell Endocrinol 2020 Dec; 518: 111038.https://doi.org/10.1016/j.mce.2020.111038
Aon YSA, Kadhim SJ, Al-Samarriae AY. Studying the genotype of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) Gene (rs641081C>A) in Iraqi Samples with Acromegaly Pituitary Adenoma. Baghdad Sci J. 2022 Dec 1; 19(6 SE-article): 1167. https://doi.org/10.21123/bsj.2022.6104
Hameed A. Assessment the Apelin, Glutathione S-transferase Polymorphism and some of Biochemical Parameters in Acromegaly Patients. PhD [dissertation]. Baghdad: College of Science for Women –University of Baghdad; 2019.
Farhan LO, Abed BA, J. KG, Salman IN. "Insulin Like Growth Factor Binding Protein 7 as a Novel Diagnostic Marker in Sera of Iraqi Patients with Acromegaly. Baghdad Sci J. 2023; 20(3): 979-985, https://doi.org/10.21123/bsj.2023.7797
Tabur S, Sezen H, Korkmaz H, Ozkaya M, Akarsu E. High Prolidase Levels may be a Marker of Irreversible Extracellular Matrix Changes in Controlled Acromegaly Patients?. Exp Clin Endocrinol Diabetes. 2016; 124(02): 82–6.https://doi.org/10.1055/s-0035-1564200
Moller N, Vendelbo MH, Kampmann U, Christensen B, Madsen M, Norrelund H, et al. Growth hormone and protein metabolism. Clin Nutr. 2009 Dec; 28(6): 597–603.https://doi.org/10.1016/j.clnu.2009.08.015
Hamwi GJ, Skillman TG, Tufts KC. Acromegaly. Am J Med. 1960 Oct; 29(4): 690–9. https://doi.org/10.1016/0002-9343(60)90101-7
Marques LR, Diniz TA, Antunes BM, Rossi FE, Caperuto EC, Lira FS, et al. Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front Physiol. 2018; 9: 526 https://doi.org/10.3389/fphys.2018.00526
Takeda R, Tatami R, Ueda K, Sagara H, Nakabayashi H, Mabuchi H. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Eur J Endocrinol. 1982; 100(3): 358–62. https://doi.org/10.1530/acta.0.1000358
Beentjes JAM, van Tol A, Sluiter WJ, Dullaart RPF. Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atheroscler. 2000; 153(2): 491–8.https://doi.org/10.1016/s0021-9150(00)00433-0
Downloads
Issue
Section
License
Copyright (c) 2024 Fatima Khazaal Malek, Salma Abdul_Rudha Abbas, Baydaa Ahmed Abed
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
